Answers are grounded in this paper and cite their sources.
The development of Grave’s ophthalmopathy following radioiodine treatment for Grave’s disease is well recognized. However, development of Grave’s ophthalmopathy following radioiodine therapy given for toxic adenoma or toxic nodular goiter has been reported but very rarely. Hereby, we reported a case of a 69-year-old male patient who developed ophthalmopathy after receiving 30 mCi (1110 mBq) 131 I radioiodine treatment for a toxic nodule. In addition, a review of the current literature with regards to this topic is presented.
No takes yet. Share an insight, caveat, or question.
Ahmadieh et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: